Abstract Number: 1281 • ACR Convergence 2020
Opioid-Related Encounters as a Predictor of 30-Day Readmissions in Lupus
Background/Purpose: One in four Medicare hospitalizations with systemic lupus erythematosus (SLE) results in readmission within 30 days, with “injuries and poisonings” as the second most…Abstract Number: 1422 • ACR Convergence 2020
Healthcare Utilization Among Patients Diagnosed with ANCA-Associated Vasculitis Between 2007 and 2014 in a Multi-Center Cohort Linked to Medicare Claims Data
Background/Purpose: ANCA-associated vasculitis (AAV) leads to complications that contribute to poor quality of life and survival. Systemic vasculitis is associated with high healthcare utilization but…Abstract Number: 1758 • ACR Convergence 2020
Prevalence and Incidence of Infection and Venous Thromboembolism in Rheumatoid Arthritis Patients Newly Initiating Various DMARD Classes: Real-World Analysis of 2012–2016 US Medicare Data
Background/Purpose: RA patients have an increased risk of infection1 and venous thromboembolism (VTE)2. Although rates of serious infection and VTE have been reported for Medicare…Abstract Number: 258 • 2019 ACR/ARP Annual Meeting
Health Services Utilization as Recommended by the American Diabetes Association Among Middle-Aged Patients Disabled with Rheumatoid Arthritis and Diabetes Mellitus
Background/Purpose: Medicare beneficiaries who are disabled (coverage by the Social Security Disability Insurance (SSDI)) with rheumatoid arthritis (RA) and diabetes mellitus (DM) and under 65…Abstract Number: 953 • 2019 ACR/ARP Annual Meeting
Treatment Patterns and Persistency Following the First Biologic DMARD in Patients with Rheumatoid Arthritis: Real-World Analysis of 2012–2016 US Medicare Data
Background/Purpose: In RA patients not meeting treat-to-target goals despite treatment with a biologic (b)DMARD, ACR guidelines1 recommend using other targeted immunomodulators (TIM): TNF-α inhibitor (TNFi),…Abstract Number: 1426 • 2019 ACR/ARP Annual Meeting
Impact of TNF Inhibitor Cycling with Adalimumab and Etanercept vs Switching to Tofacitinib
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. It was approved for RA by the US FDA in Nov 2012. TNFi…Abstract Number: 2333 • 2019 ACR/ARP Annual Meeting
Risk of Incident Myocardial Infarction Among Disabled Patients with Rheumatoid Arthritis Who Were Beneficiaries of the Social Security Disability Insurance
Background/Purpose: Patients with RA have high risk for myocardial infarction (MI). A meta-analysis showed that the age and sex adjusted pooled relative risk of MI…Abstract Number: 2176 • 2018 ACR/ARHP Annual Meeting
The Association of Gout with Incident Giant Cell Arteritis in Older Adults
Background/Purpose: Giant cell arteritis (GCA) is a vasculitis that affects large and medium sized arteries in people 50 years or older. Gout, the most common…Abstract Number: 2226 • 2018 ACR/ARHP Annual Meeting
Gout and the Risk of Incident Dementia in the Elderly: A Medicare Claims Study
Background/Purpose: The pursuit of a link between gout/hyperuricemia and dementia has led to contradictory results. Most observational studies, including population-based studies, showed that hyperuricemia was…Abstract Number: 293 • 2018 ACR/ARHP Annual Meeting
Temporal Trends and Factors Associated with Bisphosphonate Drug Holidays
Background/Purpose: Safety concerns related to osteoporosis (OP) medication use and temporary or permanent cessation of bisphosphonate therapy (e.g. ‘drug holidays’) have generated appreciable attention in…Abstract Number: 519 • 2018 ACR/ARHP Annual Meeting
Marginal Structure Modeling of Association between Disease Activity and Hospitalized Infection Among Patients in a Rheumatoid Arthritis Registry
Background/Purpose: Higher disease activity might be associated with a higher risk of developing infections among patients with rheumatoid arthritis (RA). Since no randomized trial has…Abstract Number: 885 • 2018 ACR/ARHP Annual Meeting
Herpes Zoster in Tofacitinib Users with and without Concomitant Methotrexate and Glucocorticoids
Background/Purpose: An increased incidence of herpes zoster (HZ) has been observed with Janus kinase inhibitors such as tofacitinib (TOF). However, among TOF users, a potentially…Abstract Number: 894 • 2018 ACR/ARHP Annual Meeting
Cancer Risk in Ankylosing Spondylitis in United States Medicare Beneficiaries: Detection of a Chronic Non Steroidal Anti-Inflammatory Drug Use Signature
Background/Purpose: Few studies have examined risk of cancer in ankylosing spondylitis (AS) since the end of the radiation therapy era. With greater use of biologics,…Abstract Number: 1242 • 2018 ACR/ARHP Annual Meeting
Rheumatologists Participating in the RISE Registry Succeeded in the First Year of the Merit-Based Incentive Payment System (MIPS)
Background/Purpose: Under the Medicare Access and CHIP Reauthorization Act (MACRA), rheumatologists face financial repercussions through the Merit-Based Incentive Payment System (MIPS) based on performance on…Abstract Number: 2132 • 2018 ACR/ARHP Annual Meeting
All-Cause Mortality, Hospitalization, and Systemic Lupus Erythematosus (SLE) Related Complications in 2011-2015 Medicare Beneficiaries with SLE
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at higher risk of complications such as heart attack and renal disease. We aimed to estimate all-cause…
ACR Meeting Abstracts